Efficacy of Deferasirox (Exjade®) in Modulation of Iron Overload in Patients withβ-Thalassemia Intermedia

Autor:	Mehran Karimi, Sanaz Safaei, Sezaneh Haghpanah, Shahla Ansari, Azita Azarkeyvan, Nargess Arandi, Mohammadreza Bordbar
Rok vydání:	2015
Předmět:	Adult Male medicine.medical_specialty Iron Overload Adolescent Clinical Biochemistry Iron Chelating Agents Benzoates Gastroenterology Young Adult Oral administration Internal medicine medicine Humans In patient Chelation therapy Child Serum ferritin Genetics (clinical) biology business.industry beta-Thalassemia Biochemistry (medical) Deferasirox Hematology Triazoles medicine.disease Hemolysis Ferritin Treatment Outcome Ferritins Immunology biology.protein Erythropoiesis Female business medicine.drug
Zdroj:	Hemoglobin. 39:327-329
ISSN:	1532-432X 0363-0269
DOI:	10.3109/03630269.2015.1057735
Popis:	Because of insufficient erythropoiesis, peripheral hemolysis and increased gastrointestinal iron absorption, iron overload is still a matter of debate in β-thalassemia intermedia (β-TI) patients, which can be overcome using iron chelators. However, data on use of iron chelators in β-TI patients is highly restricted. The aim of this study was to evaluate the efficacy of oral administration of deferasirox (Exjade(®) or DFX) by assessment of serum ferritin levels in β-TI patients. In this quasi-experimental study, 50 β-TI patients with serum ferritin levels1000 ng/mL were selected and received oral DFX for 12 consecutive months. Iron overload was measured by checking serum ferritin levels every 2 months and the results were compared with the baseline level. The mean serum ferritin was decreased during 1 year of chelation therapy without any toxic effect. Although the difference between baseline ferritin and ferritin levels at the end of second month was not remarkable (p = 0.88), a significant reduction in serum ferritin was observed after 4 (p = 0.01), 6 (p = 0.001), 8 (p 0.001), 10 (p 0.001) and 12 months (p 0.001) of chelation therapy compared to its baseline levels. There was no correlation between baseline ferritin levels and age (p = 0.574). In addition, no statistically significant difference was observed about change in serum ferritin levels after 6 and also 12 months of therapy between patients who had undergone splenectomy and those who did not (p = 0.796 and 0.859, respectively). Iron chelation therapy with DFX is safe and effective in reducing serum ferritin levels in β-TI patients who suffer from side effects of iron overload.
Databáze:	OpenAIRE
Externí odkaz:	https://explore.openaire.eu/search/publication?articleId=doi_dedup___::decfe249bbee8217f55f68b5020e9567 https://doi.org/10.3109/03630269.2015.1057735 Zobrazit plný text záznamu Plný text ve formátu PDF Plný text ve formátu HTML
Nepřihlášeným uživatelům se plný text nezobrazuje	K zobrazení výsledku je třeba se přihlásit.